Zealand boss considers several new indications for blood sugar remedy

CEO of Zealand Pharma, Emmanuel Dulac, reports that the company is investigating several possible indications for the company's blood sugar drug dasiglucagon, after the firm has started new phase 2 studies with a new indication.

Emmanuel Dulac, CEO of Zealand Pharma

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles